CN1446550A - Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method - Google Patents
Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method Download PDFInfo
- Publication number
- CN1446550A CN1446550A CN 02109342 CN02109342A CN1446550A CN 1446550 A CN1446550 A CN 1446550A CN 02109342 CN02109342 CN 02109342 CN 02109342 A CN02109342 A CN 02109342A CN 1446550 A CN1446550 A CN 1446550A
- Authority
- CN
- China
- Prior art keywords
- herba
- radix
- medicine
- rhinitis
- chronic rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating acute and chronic rhinitis is prepared from 11 Chinese-medicinal materials including bear gall powder, mint, Chuan-xiong rhizome, red peony root, liquorice root, etc. Its advantages are high curative effect and no by-effect.
Description
Technical field: having the present invention relates to a kind of medicine for the treatment of acute or chronic rhinitis, is the Chinese patent medicine of the acute or chronic rhinitis of feedstock production specifically with Chinese medicine; The invention still further relates to the preparation method of this medicine.
Background technology: existing acute or chronic rhinitis is commonly encountered diseases, a frequently-occurring disease clinically, all can take place throughout the year, and the old children of male woman all can suffer from.Especially in the northern area of China, winter climate cold, drying, it is just more to suffer from this sick chance.It gives daily life and the healthy a lot of misery and inconvenient of bringing.The patient removes the misery of disease for this reason, provides a kind of effective medicine to them, is the duty-bound responsibility of medical worker.
The cardinal symptom of acute or chronic rhinitis is obstructed, the baryo,dmia of nose, and nasal mucus is in vain sticking or Huang is thick, have a headache and fever etc.Nasal obstruction, anosmia then appear in the patient with severe symptoms, flow symptoms such as the thick tears of yellow pus, dizziness.It causes that the pain factor mostly is that ailment said due to cold or exposure is attacked outward, Lung Qi obstraction, strongly fragrant and heat-transformation, pathogenic heat are stranded in the nose key and must not lead off and send out and be primary disease.
Be used at present the medicine of primary disease treatment all not very goodly both at home and abroad, treatment mostly is symptomatic treatment.Antibacterials commonly used or antibiosis be infection usually, but prolonged application then develops immunity to drugs.Also select some topical therapeutic medicines such as relief of symptoms such as ephedrine liquid and naphazoline for use, but long-term extensive application can make nasal mucosa knock-on property hyperemia and produce medicamentous rhinitis.
Summary of the invention: the purpose of this invention is to provide Chinese medicine of a kind of acute or chronic rhinitis and preparation method thereof.
Above-mentioned purpose realizes by following technical scheme:
The Chinese medicine of treatment acute or chronic rhinitis, comprising following weight proportioning medical material:
Fel Ursi powder 0.5～5 Flos Magnoliae 15～30 Herba Houttuyniae 40～60
Radix Scutellariae 20～35 Fructus Xanthii 15～30 Herba Asaris 5～10
Herba Schizonepetae 10～25 Herba Menthaes 5～15 Rhizoma Chuanxiongs 10～25
Radix Paeoniae Rubra 10～25 Radix Glycyrrhizaes 5～20
The Chinese medicine of above-mentioned acute or chronic rhinitis, wherein the weight proportion of each raw material is:
Fel Ursi powder 1 Flos Magnoliae 18 Herba Houttuyniae 50 Radix Scutellariaes 25
Fructus Xanthii 18 Herba Asaris 6 Herba Schizonepetae 12 Herba Menthaes 7
Rhizoma Chuanxiong 12 Radix Paeoniae Rubra 18 Radix Glycyrrhizaes 6
The medicine of above-mentioned treatment acute or chronic rhinitis, said medicament are said dosage forms on any pharmaceutics.
The preparation method of the medicine of above-mentioned treatment acute or chronic rhinitis:
Get Radix Paeoniae Rubra earlier, pulverize standby; With the Radix Scutellariae section,, filter with boiling water extraction; Residue discards, and it is 1.05～1.08 clear paste that filtrate is concentrated into relative density.Adding hydrochloric acid, to transfer PH be 1～2, static, filter, precipitation is dry and pulverize.Flos Magnoliae, Herba Schizonepetae, Herba Asari, Herba Menthae, Rhizoma Chuanxiong five kinds of Chinese medicine are extracted volatile oil, add Radix Glycyrrhizae, Herba Houttuyniae, Fructus Xanthii in the medicinal residues, use water extraction, filter; Residue discards, and filtrate is concentrated into clear paste; Add ethanol, making it content is 65%; Filter.Reclaim ethanol, be concentrated into the extractum of clear paste shape.Get Fel Ursi powder, Radix Scutellariae extract, Radix Paeoniae Rubra powder, add above-mentioned extractum successively, alcohol granulation is used in cold drying, pulverizing, and cold drying sprays into volatile oil, and close profit 2 hours makes tablet.This technical scheme has following beneficial effect:
One.This product by wind and heat dispersing, gently declare in its prescription unique.We reuse heat and toxic materials clearing away medicine such as Fel Ursi powder, Herba Houttuyniae, Radix Scutellariae, the pathogenic bacteria that suppresses focus grows, strengthens leukocytic phagocytic function, can also improve the vigor of lysozyme in patients serum and the body fluid, thereby quicken the reparation of nose focus, avoid the outbreak repeatedly of rhinitis.Adopt medicines such as Herba Xanthii, Flos Magnoliae, increase the blood flow rate of nasal membrane, microcirculation improvement increases local nutrition, promotes the quickly-healing of nose focus; Simultaneously in therapeutic process, do not restrain blood vessel, so can not take place to cause the drawback of medicamentous rhinitis, and have good anti-allergic effects owing to the paralysis smooth muscle produces the vasodilation of knock-on property.Cards such as the migraine that Drug therapy rhinitis such as employing Herba Asari, Rhizoma Chuanxiong cause, giddy, the release of Herba Asari inflammation-inhibiting medium and the hypertrophy of connective tissue play antiphlogistic effect, thereby the card of nasal obstruction are alleviated simultaneously.All medicines share, and fundamentally alleviate rhinitis patient's misery, quicken to take a turn for the better, and eliminate focus, reduce the probability of outbreak repeatedly.Zoopery proves, that medicine of the present invention has is significantly antibiotic, antiinflammatory, antianaphylaxis, analgesia and refrigeration function.
Two, the present invention proves through zoopery, is safety non-toxic, and acute or chronic rhinitis is had certain curative effect, and its toxicology and pharmacodynamics test data are as follows:
1. give mouse stomach once with Cmax and the maximum gastric capacity of irritating, fail to obtain the LD50 of mice.With Cmax and the maximum gastric capacity of irritating, in administration successive administration on the same day three times, each 0.8ml/20g body weight, each 4 hours at interval, recording mice day maximum tolerated dose was 48g/kg, is equivalent to 631.58 times of clinical consumption per day approximately.Show thus: consumption per day of the present invention is safe.
2. long term toxicity test: respectively with 2g/kg, 4g/kg, 8g/kg are equivalent to (26.3,52.6,105.2 times) of clinical consumption per day approximately and give the administration of Wistar rat oral gavage, every day 1 time, continuous 12 weeks.The result shows: the general state of animal, behavioral activity and diet situation and matched group no significant difference.The equal no significant difference of hematology, pathology, histology, liver function and organ coefficient and matched group, it is safe and reliable that prompting is taken for a long time.
3. antibacterial tests: treated in vitro is the result show: medicine of the present invention all has in various degree inhibitory action to staphylococcus aureus, Hemolytic streptococcus, Diplococcus pneumoniae, Bacillus typhi, bacillus pyocyaneus, escherichia coli, paratyphoid bacillus A, sonne bacillus, modification bacillus, dysentery bacterium etc.
4. antiinflammatory test:
(1) to the test of mice dimethylbenzene inflammatory capillary permeability: get Kunming mouse, every day gastric infusion once, continuous three days, positive control drug is rhinitis tablet, chlorphenamine, the blank group is given the normal saline with volume, last administration 60min, every Mus body angular vein is injected 1% Yi Wensilan (10ml/kg), simultaneously at each 3 melted paraxylene of mice two ear places, put to death animal after 20 minutes, take off two ear homalographic tissues and immerse in water-acetone, centrifugal after 24 hours, get supernatant photometry density value, the results are shown in following table.
Influence to the increase of mice dimethylbenzene inflammatory capillary permeability
Group dosage number of animals OD value P value
(g/kg) (only) (X ± SD)
The heavy dose of group 2.188 10 0.025 ± 0.01＜0.01 of examination
Dosage group 1.094 10 0.030 ± 0.01＜0.01 in testing
Medicine small dose group 0.547 10 0.055 ± 0.02＜0.01
Rhinitis tablet 0.840 10 0.035 ± 0.02＜0.01
Chlorphenamine 0.05 10 0.020 ± 0.01＜0.01
Normal saline is with volume 10 0.150 ± 0.02
Melted paraxylene 10 0.100 ± 0.01＜0.01
Normal mouse
The result shows: the increase of the mice inflammatory capillary permeability that medicine xylol of the present invention causes has the obvious suppression effect.
(2) test that capillary permeability due to rat histamine and the 5-HT is increased: get the Wistar rat, every day gastric infusion once, continuous three days, after the last administration 1 hour, in rat back difference intradermal injection histamine (1 μ g/ml, 0.05 μ g/100g body weight), 5-HT (1 μ g/ml, 0.05 μ g/100g body weight), sublingual vein is injected 1% Yi Wensilan (4ml/kg) immediately, and 15 minutes sacrificed by decapitation are peeled off, cut the painted skin in back, put into water-acetone soln and soak after 48 hours, press preceding method and survey the OD value, the results are shown in following table:
The influence that capillary permeability due to rat histamine and the 5-HT is increased
| Group | Dosage (g/kg) | Number of animals (only) | Proinflammatory agent | The OD value (X ± SD) | The P value | |
| Investigational agent | Dosage group small dose group rhinitis tablet chlorpheniramine physiological saline is not given the normal mouse of proinflammatory agent in heavy dose of group | 1.276 0.638 0.319 0.500 0.030 same volume | ????10 ????10 ????10 ????10 ????10 ????10 ????10 | Histamine 5-HT histamine 5-HT histamine 5-HT histamine 5-HT histamine 5-HT histamine 5-HT histamine 5-HT | ??0.045±0.020 ??0.065±0.035 ??0.050±0.025 ??0.080±0.040 ??0.070±0.035 ??0.095±0.060 ??0.065±0.040 ??0.085±0.035 ??0.025±0.010 ??0.020±0.010 ??0.015±0.060 ??0.015±0.035 ??0.100±0.030 ??0.090±0.035 | ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 ??＜0.01 |
The result shows: medicine of the present invention has tangible antagonism (P＜0.01) to the rat capillary permeability increase due to histamine and the 5-HT.
5. to the test of foot swelling due to the rat Ovum Gallus domesticus album: get the Wistar rat, every day gastric infusion once, continuous three days, in last give through after feedwater load (2.5ml/100g) immediately, after 30 minutes in every the right back ankle subcutaneous injection of rat fresh egg white 0.1ml, injected respectively behind the Ovum Gallus domesticus album 0.5 hour, 2 hours, 4 hours, 6 hours, measuring the girth of ankle joint with tape, is the swollen joint expansibility with the difference of left and right sides ankle joint girth, the results are shown in following table.
Influence to foot swelling due to the rat Ovum Gallus domesticus album
The group dosage number of animals paw swelling (mm of X ± SD)
(g/kg) the heavy dose of group 1.276 10 4.8 ± 1.2 of (only) 0.5h 1h 2h 4h 6h examination
*4.7 ± 1.1
*4.5 ± 1.2
*4.0 ± 1.1
*3.6 ± 0.8
*Dosage group 0.638 10 5.1 ± 1.3 4.8 ± 0.8 in testing
*4.7 ± 1.8 4.3 ± 0.9
*3.9 ± 1.1 medicine small dose group 0.319 10 5.4 ± 1.1 5.1 ± 0.9 4.8 ± 0.9 4.5 ± 1.1 4.0 ± 1.2
Rhinitis tablet 0.500 10 4.9 ± 1.2
*4.8 ± 1.4
*4.5 ± 1.1
*4.1 ± 1.2
*3.8 ± 1.1
*
Dexamethasone 0.030 10 4.2 ± 1.1
*4.0 ± 1.3
*3.8 ± 1.2
*3.0 ± 0.6
*2.3 ± 0.8
*
Normal saline is with volume 10 6.3 ± .4 6.4 ± 1.2 6.0 ± 1.8 5.6 ± 1.4 5.0 ± 1.2
*P＜0.05??
**p＜0.01
The result shows: medicine of the present invention has certain inhibitory action to foot swelling due to the rat Ovum Gallus domesticus album.
6. to the test of mice passive cutaneous anaphylaxis, PCA
Get Kunming mouse, get antiserum and add normal saline and be diluted to 1: 10, two points of every Mus stomach wall intradermal injection, every some 0.03ml, every day gastric infusion once, continuous two days.Sensitization is carried out antigen and is attacked after 48 hours, 0.2ml/ only for tail vein injection Radix Trichosanthis 0.5mg/ml (with 1% Yi Wensilan-normal saline preparation), behind the 20min, the sacrificed by decapitation animal, the upset skin of abdomen takes off blue speckle skin, soaked 48 hours with acetone-mixed liquor of normal saline 5ml, the centrifuging and taking supernatant is surveyed the OD value at the 610nm place.The results are shown in following table:
Influence to the mice passive cutaneous anaphylaxis, PCA
Group dosage number of animals OD value P value
(g/kg) (only) (X ± SD)
The heavy dose of group 2.188 10 0.05 ± 0.03＜0.01 of examination
Dosage group 1.094 10 0.08 ± 0.02＜0.01 in testing
Medicine small dose group 0.547 10 0.10 ± 0.02＜0.01
Rhinitis tablet 0.840 10 0.12 ± 0.06＜0.01
Dexamethasone 1.2 (mg) 10 0.04 ± 0.01＜0.01
Normal saline is with volume 10 0.18 ± 0.05
The result shows: medicine of the present invention has significant antagonism (P＜0.01) to passive cutaneous anaphylaxis, PCA due to the mice Radix Trichosanthis gel aluminum hydroxide.
7. heat test is conciliate in the analgesic test
Get Kunming mouse, every day gastric infusion once, continuous three days, after the last administration 1 hour, every Mus lumbar injection 0.6% glacial acetic acid (0.1ml/10g body weight), behind the record injection glacial acetic acid in the 20min each Mus turn round the body number of times, the results are shown in following table:
P value in the 20min behind the group dosage number of animals notes acetic acid
(g/kg) (only) number of torsions (X ± SD)
The heavy dose of group 2.188 10 0.05 ± 0.03＜0.01 of examination
Dosage group 1.094 10 0.08 ± 0.02＜0.01 in testing
Medicine small dose group 0.547 10 0.10 ± 0.02＜0.01
Rhinitis tablet 0.840 10 0.12 ± 0.06＜0.01
Dexamethasone 0.060 10 0.04 ± 0.01＜0.01
Normal saline is with volume 10 0.18 ± 0.05
The result shows: medicine of the present invention has significant antagonism (P＜0.01, P＜0.05) to glacial acetic acid induced mice writhing response.
Three, invention is to by 2, Mus heating due to the 2, 4-dinitrophenol and the rabbit due to the typhoid fever bacterium
Heating all has certain inhibitory action.
Four, through clinical trial certificate, that medicine of the present invention has is significantly antibiotic, antiinflammatory, antianaphylaxis, analgesia and refrigeration function.
Embodiment 1:
A kind of Chinese medicine for the treatment of acute or chronic rhinitis is comprising following weight proportioning medical material (gram or kilogram): Fel Ursi powder 0.5～5 Flos Magnoliae 15～30 Herba Houttuyniae 40～60 Radix Scutellariaes 20～35 Fructus Xanthii 15～30 Herba Asaris 5～10 Herba Schizonepetae 10～25 Herba Menthaes 5～15 Rhizoma Chuanxiongs 10～25 Radix Paeoniae Rubra 10～25 Radix Glycyrrhizaes 5～20
Embodiment 2:
The Chinese medicine of embodiment 1 described acute or chronic rhinitis, wherein the weight proportion of each raw material is:
Fel Ursi powder 1 Flos Magnoliae 18 Herba Houttuyniae 50 Radix Scutellariaes 25
Fructus Xanthii 18 Herba Asaris 6 Herba Schizonepetae 12 Herba Menthaes 7
Rhizoma Chuanxiong 12 Radix Paeoniae Rubra 18 Radix Glycyrrhizaes 6
Above-mentioned each component is made medicine production method of the present invention is:
1. get Radix Paeoniae Rubra earlier, it is standby to be ground into fine powder.
2. with Radix Scutellariae section, with boiling water extraction, filter, residue discards, and it is 1.05～1.08 clear paste (80 ℃) that filtrate is condensed into relative density.Add hydrochloric acid, transfer PH to be 1～2, static, filter, will precipitate dry, pulverizing.
3. five kinds of Chinese medicine such as Flos Magnoliae, Herba Schizonepetae, Herba Asari, Herba Menthae, Rhizoma Chuanxiong are extracted volatile oil, and with separating of oil go out standby.
4. with adding Radix Glycyrrhizae, Herba Houttuyniae, Fructus Xanthii in the above-mentioned medicinal residues, use water extraction, filter; Residue discards, and filtrate is condensed into clear paste, adds ethanol then, makes pure content reach 65%; Filter, reclaim ethanol, and be concentrated into the extractum of clear paste shape.
5. get Fel Ursi powder, Radix Scutellariae extract, Radix Paeoniae Rubra powder and go into above-mentioned extractum in successively, cold drying is pulverized; Use alcohol granulation, cold drying sprays into volatile oil, and close profit 2 hours is made corresponding dosage forms such as tablet, powder, spraying machine, oral liquid or injection as required.
Embodiment 3:
A kind of Chinese medicine for the treatment of acute or chronic rhinitis takes by weighing raw material (g) by following proportioning
Fel Ursi powder 13.4 Flos Magnoliaes 250 Herba Houttuyniae 167 Radix Scutellariaes 333
Fructus Xanthii (stir-fry) 250 Herba Asaris 83 Herba Schizonepetae 167 Herba Menthaes 100
Rhizoma Chuanxiong 167 Radix Paeoniae Rubra 250 Radix Glycyrrhizaes 83
Production method is as follows:
Get Radix Paeoniae Rubra earlier, pulverize standbyly, with Radix Scutellariae section, with boiling water extraction, filter, residue discards; It is 1.05～1.08 clear paste that filtrate is concentrated into relative density.Adding hydrochloric acid, to transfer PH be 1～2, static, filter, precipitation is dry, pulverize.Flos Magnoliae, Herba Schizonepetae, Herba Asari, Herba Menthae, Rhizoma Chuanxiong five kinds of Chinese medicine are extracted volatile oil, add Radix Glycyrrhizae, Herba Houttuyniae, Fructus Xanthii in the medicinal residues, use water extraction, filter, residue discards, and filtrate is concentrated into clear paste, adds ethanol, and making it content is 65%.Filter, reclaim ethanol, be concentrated into the extractum of clear paste shape.Get Fel Ursi powder, Radix Scutellariae extract, Radix Paeoniae Rubra powder, add above-mentioned extractum successively, alcohol granulation is used in cold drying, pulverizing, and cold drying sprays into volatile oil, and close profit 2 hours makes 1000 in tablet.
Usage and consumption: oral, each 4, every day 3 times.
Claims (4)
1. Chinese medicine for the treatment of acute or chronic rhinitis is characterized in that: comprising following weight proportioning medicine:
Fel Ursi powder 0.5～5 Flos Magnoliae 15～30 Herba Houttuyniae 40～60
Radix Scutellariae 20～35 Fructus Xanthii 15～30 Herba Asaris 5～10
Herba Schizonepetae 10～25 Herba Menthaes 5～15 Rhizoma Chuanxiongs 10～25
Radix Paeoniae Rubra 10～25 Radix Glycyrrhizaes 5～20
2. according to the Chinese medicine of the described acute or chronic rhinitis of claim 1, it is characterized in that: wherein the weight proportion of each raw material is:
Fel Ursi powder 1 Flos Magnoliae 18 Herba Houttuyniae 50 Radix Scutellariaes 25
Fructus Xanthii 18 Herba Asaris 6 Herba Schizonepetae 12 Herba Menthaes 7
Rhizoma Chuanxiong 12 Radix Paeoniae Rubra 18 Radix Glycyrrhizaes 6
3. according to the medicine of claim 1,2 described treatment acute or chronic rhinitis, it is characterized in that said medicament is a said dosage form on any pharmaceutics.
4. the preparation method of the medicine of claim 1 or 2 or 3 described treatment acute or chronic rhinitis is characterized in that:
Get Radix Paeoniae Rubra earlier, pulverize standby; With the Radix Scutellariae section,, filter with boiling water extraction; Residue discards, and it is 1.05～1.08 clear paste that filtrate is concentrated into relative density.Adding hydrochloric acid, to transfer PH be 1～2, static, filter, precipitation is dry and pulverize.Flos Magnoliae, Herba Schizonepetae, Herba Asari, Herba Menthae, Rhizoma Chuanxiong five kinds of Chinese medicine are extracted volatile oil, add Radix Glycyrrhizae, Herba Houttuyniae, Fructus Xanthii in the medicinal residues, use water extraction, filter; Residue discards, and filtrate is concentrated into clear paste; Add ethanol, making it content is 65%; Filter.Reclaim ethanol, be concentrated into the extractum of clear paste shape.Get Fel Ursi powder, Radix Scutellariae extract, Radix Paeoniae Rubra powder, add above-mentioned extractum successively, alcohol granulation is used in cold drying, pulverizing, and cold drying sprays into volatile oil, and close profit 2 hours makes tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02109342 CN1261125C (en) | 2002-03-22 | 2002-03-22 | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02109342 CN1261125C (en) | 2002-03-22 | 2002-03-22 | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1446550A true CN1446550A (en) | 2003-10-08 |
| CN1261125C CN1261125C (en) | 2006-06-28 |
Family
ID=28048519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02109342 Expired - Lifetime CN1261125C (en) | 2002-03-22 | 2002-03-22 | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1261125C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100386105C (en) * | 2005-03-11 | 2008-05-07 | 冀元成 | Chinese medicine for treating rhinitis |
| CN103565972A (en) * | 2013-10-24 | 2014-02-12 | 安徽工贸职业技术学院 | Preparation method of traditional Chinese medicine (TCM) composition for treating allergic rhinitis |
| CN103566009A (en) * | 2013-10-24 | 2014-02-12 | 安徽工贸职业技术学院 | Traditional Chinese medicine (TCM) composition for treating acute and chronic rhinitis |
| CN105194505A (en) * | 2015-08-31 | 2015-12-30 | 颜海 | Traditional Chinese medicine for treating chronic rhinitis |
-
2002
- 2002-03-22 CN CN 02109342 patent/CN1261125C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100386105C (en) * | 2005-03-11 | 2008-05-07 | 冀元成 | Chinese medicine for treating rhinitis |
| CN103565972A (en) * | 2013-10-24 | 2014-02-12 | 安徽工贸职业技术学院 | Preparation method of traditional Chinese medicine (TCM) composition for treating allergic rhinitis |
| CN103566009A (en) * | 2013-10-24 | 2014-02-12 | 安徽工贸职业技术学院 | Traditional Chinese medicine (TCM) composition for treating acute and chronic rhinitis |
| CN105194505A (en) * | 2015-08-31 | 2015-12-30 | 颜海 | Traditional Chinese medicine for treating chronic rhinitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1261125C (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1927307A (en) | Chinese herbal medicine prescription for treating cancer | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN102284022A (en) | Cough medicament and preparation method thereof | |
| CN101564458B (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| KR101416453B1 (en) | A medicine composition for treating bronchial asthma and preparative method thereof | |
| CN1883552A (en) | A Chinese medicine for treating mastopathy and method for preparing same | |
| CN1261125C (en) | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method | |
| CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN1237994C (en) | Medicine composition for preparing canker and preparing method thereof | |
| CN1283391A (en) | Extracted liquor for disinfection | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN104784621A (en) | Traditional Chinese medicine composition for treating diarrhea, and preparation method and application thereof | |
| CN103006919A (en) | Oral liquid for treating toothache and preparation method thereof | |
| CN101904962B (en) | Medicament for treating cold and preparation method thereof | |
| CN108272880B (en) | Zilpaterol compound veterinary drug composition as well as preparation method and application thereof | |
| CN101554461B (en) | Medicine for treating psoriasis and preparation method of capsule thereof | |
| CN1148201C (en) | Preparing method for auxiliary feedback treatment of disease medicine | |
| CN1053818C (en) | Ulcer powder | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN104435133A (en) | Medicament for reducing fever | |
| CN1259938C (en) | Chinese medicine compound preparation for treating cough and its preparing method | |
| CN1068219C (en) | Slow-released analgesic suppository and its preparation process | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060628 |
|
| RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20100922 |